8 October 2024 UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101.
R-Pharm Group, one of Russia’s leading pharmaceutical producers, is expanding into the market Southeast Asia, according to the company, reports The Pharma Letter’s local correspondent. 10 November 2022
News of the planned merger of Norway-based companies Nordic Nanovector and APIM Therapeutics, a privately held, clinical-stage cancer-focused biotechnology firm, saw the former’s shares fall 13.3% to 1.17 Norwegian kroner by late afternoon. 10 November 2022
German drugmaker Merck KGaA has reported net sales in the 2022 third quarter of 5.8 billion euros ($5.8 billion), in line with many analysts’ expectations, with earnings per share coming in at 2.68 euros. 10 November 2022
After months of searching for a new leader, US biotech major Biogen today announced the appointment of industry veteran Christopher Viehbacher as president and chief executive and a member of its board of directors, effective November 14. 10 November 2022
The US Food and Drug Administration (FDA) yesterday issued an emergency use authorization (EUA)for Kineret (anakinra) injection for the treatment of COVID-19 in hospitalized adults with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) 10 November 2022
The number of drugs that are disappearing from Russian pharmaceutical retail is steadily growing due to ongoing repartition of the market by the largest local players as well as Western sanctions against Russia. 10 November 2022
A strategic licensing deal has been agreed between Barcelona, Spain-based rare disease company Minoryx Therapeutics and German central nervous system (CNS) specialist Neuraxpharm. 10 November 2022
The entry of new treatments for atypical hemolytic uremic syndrome (aHUS) such as Swiss pharmaceutical giants Novartis and Roche that have strong digital experience can alter the aHUS digital landscape dynamics in Japan, says data and analytics company GlobalData. 10 November 2022
Shares of Sino-American biotech BeiGene rose as much as 3.8% to 133.97 renminbi when trading started this morning, as the company released third-quarter 2022 financial results that beat consensus forecasts. 10 November 2022
The growing US-China tension, a chilled market and a weakened China economy had Chinese biotechs re-think their strategies. However, most of them agreed that, despite all the challenges, going global is a must, said speakers at the DJSeedin innovation partnering conference held in Shanghai earlier this month. 9 November 2022
Artificial intelligence (AI)-driven drug discovery company Insilico Medicine has announced a multi-year, multi-target strategic research collaboration with French pharma major Sanofi. 9 November 2022
The checkpoint blocker Libtayo (cemiplimab-rwlc) has secured US approval for the first-line treatment of certain adults with advanced non-small cell lung cancer (NSCLC). 9 November 2022
Shares of Novavax were up as much as 3% in pre-market trading, after the US biotech released top-line results from a Phase III boosting trial for COVID-19, showing that its BA.1 vaccine candidate (NVX-CoV2373) met the primary strain-change endpoint. 9 November 2022
Hopes that the novel antibody-drug conjugate (ADC) camidanlumab tesirine (Cami) might soon secure a review under the Accelerated Approval scheme have been dashed. 9 November 2022
Denmark-based CNS specialist Lundbeck saw its shares rise nearly 4% to 28.48 Danish kroner in early trading, after the company released financial results for the first nine months of 2022. 9 November 2022
UK pharma major AstraZeneca today reported that the US Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee has voted overwhelmingly to recommend approval of PT027 (albuterol/budesonide) as a new rescue treatment in the USA for people 18 years of age and older, but was not so supportive for younger age groups. 9 November 2022
The US Food and Drug Administration (FDA) yesterday published a new draft guidance for industry, titled “Sameness Evaluations in an ANDA – Active Ingredients.” 9 November 2022
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
Sage Therapeutics’ share price fell 11% to $6 in pre-market activity on Tuesday, after it announced disappointing top-line results from LIGHTWAVE. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
The UK has launched a new Regulatory Innovation Office (RIO), with the goal of accelerating new technologies, particularly in sectors like biotech and healthcare, by reducing regulatory barriers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Some two-and-a-half years after buying the Novo Holdings portfolio company ReViral and its respiratory syncytial virus (RSV) candidate sisunatovir in a deal worth up to $525 million, US pharma giant Pfizer may have signalled an early end to the pricey project. 9 October 2024
US pharma major Bristol Myers Squibb’s recent approval from the US Food and Drug Administration (FDA) for Cobenfy (xanomeline and trospium chloride) for the treatment of adults with schizophrenia is a win for the company. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.